TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21474643
Drug: Intravenous ceftazidime
Normalized name: Ceftazidime
DrugBank: Ceftazidime (DB00438)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ceftazidime (90 mg·kg(‐1)·d(‐1), continuous administration) and amikacin (15 mg·kg(‐1)·d(‐1))
Study: 18708923
Drug: Cefuroxime (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefuroxime (1.5 g preoperative dose)
Study: 16857835
Drug: Lactulose (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactulose (25 g/d)
Study: 11827905
Drug: Amoxicillin (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin (25 mg/kg, twice daily for 5 days)
Study: 11827905
Drug: Co-trimoxazole (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-trimoxazole (4 mg/kg trimethoprim plus 20 mg/kg sulphamethoxazole, twice daily for 5 days)
Study: 10419992
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg vitamin A
Study: 10419992
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg vitamin A (among malnourished infants)
Study: 10419992
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg vitamin A (among well-nourished children)
Study: 8693619
Drug: Salmeterol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol (50 micrograms twice daily)
Study: 7966789
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no adjuvant treatment)
Study: 31335248
Drug: Visits involving
Approvals — FDA: no, EMA: no, PMDA: no
Description: Visits involving discussion of chemotherapy
Study: 7752174
Drug: celiprolol 200
Normalized name: celiprolol 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: celiprolol 200 mg or 400 mg once daily
Study: 7752174
Drug: metoprolol 100
Normalized name: metoprolol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: metoprolol 100 mg or 200 mg once daily
Study: 25148789
Drug: Intravitreal ranibizumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal ranibizumab 0.3 mg
Study: 25148789
Drug: Intravitreal ranibizumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal ranibizumab 0.5 mg
Study: 18772894
Drug: CLA (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: CLA (3 g daily) plus n-3 LC-PUFA (3 g daily)
Study: 18772894
Drug: Control oil
Normalized name: SALICYLIC ACID 29.2 mg TOPICAL LIQUID [Acne Control oil-free Cleansing]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control oil (6 g daily)
Study: 10202315
Drug: Theolong 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theolong 400 mg/day
Study: 7771486
Drug: High blood
Normalized name: Cough & Cold High Blood Pressure Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: High blood flow (400 mL/min) for 2 hours with cuprophan membrane
Study: 7771486
Drug: High blood
Normalized name: Cough & Cold High Blood Pressure Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: High blood flow (400 mL/min) for 2 hours
Study: 6116855
Drug: PRP +
Normalized name: Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRP + P vaccine (with pertussis adjuvant)
Study: 6116855
Drug: PRP vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRP vaccine alone
Study: 29226471
Drug: Cenderitide (4-hour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cenderitide (4-hour infusion)
Study: 2437837
Drug: Methylprednisolone (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone (1 mg/kg)
Study: 28077104
Drug: Flutter® therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flutter® therapy
Study: 29605819
Drug: APIC intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: APIC intervention (weekly 3-hour personalised stimulation sessions for 12 months)
Study: 22264202
Drug: NeuroFlo catheter
Normalized name: CATHETER
Approvals — FDA: no, EMA: no, PMDA: no
Description: NeuroFlo catheter treatment
Study: 19231633
Drug: A-002 (1-H-indole-3-glyoxamide)
Normalized name: heparinoids 0.002 MG/MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: A-002 (1-H-indole-3-glyoxamide) 50 mg twice daily
Study: 19231633
Drug: A-002 (1-H-indole-3-glyoxamide)
Normalized name: heparinoids 0.002 MG/MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: A-002 (1-H-indole-3-glyoxamide) 100 mg twice daily
Study: 19231633
Drug: A-002 (1-H-indole-3-glyoxamide)
Normalized name: heparinoids 0.002 MG/MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: A-002 (1-H-indole-3-glyoxamide) 250 mg twice daily
Study: 10742877
Drug: Family therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family therapy and Family group psychoeducation
Study: 8458314
Drug: Metronidazole +
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metronidazole + High energy supplement (3.31 MJ daily for 3 months)
Study: 29956526
Drug: Pharmaceutical care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical care provided by community pharmacists in collaboration with diabetologists and diabetes advisors
Study: 23809512
Drug: L-NMMA (nonselective
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-NMMA (nonselective NO-inhibitor)
Study: 12051214
Drug: Hypothetical pain
Normalized name: Dermoplast Pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypothetical pain medication information leaflet
Study: 12680738
Drug: Temazepam (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temazepam (20 mg)
Study: 10941
Drug: Nitrazepam (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrazepam (10 mg)
Study: 27037462
Drug: Long-interval misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-interval misoprostol (2 tablets of 400 μg at 12 hours and 2 placebo tablets at 3 hours before procedure)
Study: 20678673
Drug: Donepezil 23
Normalized name: donepezil 23 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donepezil 23 mg/d
Study: 11810088
Drug: Sublingual misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sublingual misoprostol (50 microg, repeated every 4 hours to a maximum of 5 doses)
Study: 11810088
Drug: Oral misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral misoprostol (50 microg, repeated every 4 hours to a maximum of 5 doses)
Study: 10513854
Drug: Paroxetine (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine (mean dose = 24.5 mg/day)
Study: 10513854
Drug: Nortriptyline (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nortriptyline (mean dose = 51.3 mg/day; mean blood level = 85.5 ng/mL)
Study: 7491235
Drug: RRV-S1 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RRV-S1 vaccine (4 x 10(4) plaque-forming units)
Study: 7491235
Drug: RRV-TV vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RRV-TV vaccine (4 x 10(4) plaque-forming units)
Study: 7491235
Drug: RRV-S1 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RRV-S1 vaccine
Study: 1834395
Drug: Immediate-release disopyramide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release disopyramide (400 mg/day)
Study: 1834395
Drug: Slow-release disopyramide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow-release disopyramide (500 mg/day)
Study: 23236367
Drug: Single-dose albendazole
Normalized name: Albendazole
DrugBank: Albendazole (DB00518)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-dose albendazole during pregnancy
Study: 23236367
Drug: Quarterly single-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quarterly single-dose albendazole during childhood
Study: 20411695
Drug: Sleep restriction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sleep restriction therapy plus hypnotic withdrawal (SR+HW)
Study: 15725695
Drug: Fluvastatin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin (20 mg/d) after crossover to Pravastatin
Study: 15725695
Drug: Pravastatin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin (10 mg/d) after crossover to Fluvastatin
Study: 15725695
Drug: Fluvastatin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin (20 mg/d) and Pravastatin (10 mg/d)
Study: 8595682
Drug: Intramuscular meperidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular meperidine (50 mg) in the deltoid
Study: 2653846
Drug: Radiotherapy +
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radiotherapy + endocrine therapy
Study: 2653846
Drug: Radiotherapy +
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radiotherapy + chemotherapy
Study: 2653846
Drug: Radiotherapy +
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radiotherapy + endocrine therapy + chemotherapy
Study: 2653846
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of hormone treatment and chemotherapy
Study: 15047035
Drug: Propranolol (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (60 mg)
Study: 21934690
Drug: Weekly docetaxel/gemcitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly docetaxel/gemcitabine followed by erlotinib (arm A)
Study: 21934690
Drug: Erlotinib followed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib followed by weekly docetaxel/gemcitabine (arm B)
Study: 8922653
Drug: Ibandronate 2.5
Normalized name: ibandronate 2.5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibandronate 2.5 mg
Study: 31857268
Drug: Anticoagulation medications
Normalized name: CPDA-1 Anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticoagulation medications
Study: 24626851
Drug: Simeprevir 100
Normalized name: Simeprevir
DrugBank: Simeprevir (DB06290)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Simeprevir 100 mg QD with peginterferon and ribavirin for 24 weeks (SMV24)
Study: 24626851
Drug: Simeprevir 100
Normalized name: Simeprevir
DrugBank: Simeprevir (DB06290)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Simeprevir 100 mg QD with peginterferon and ribavirin for 12 weeks (SMV12)
Study: 14500804
Drug: Parathyroid hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Parathyroid hormone (1-84) 100 microg
Study: 10663814
Drug: Fentanyl continuous
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl continuous infusion (2 microg/kg per h)
Study: 9065133
Drug: Heparin and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin and low-dose aspirin
Study: 6140541
Drug: Nicotinic acid
Normalized name: Nicotinic acid
DrugBank: Niacin (DB00627)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotinic acid 1 g orally in divided doses
Study: 28158276
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (education, behavioral strategies, and oral laxatives).
Study: 25998212
Drug: DA-3803 (test
Approvals — FDA: no, EMA: no, PMDA: no
Description: DA-3803 (test formulation)
Study: 19634573
Drug: metformin +
Approvals — FDA: no, EMA: no, PMDA: no
Description: metformin + glimepirid (3 mg in the morning)
Study: 17666915
Drug: Valsartan 80
Normalized name: valsartan 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan 80 mg/day
Study: 19958075
Drug: Irbesartan 150
Normalized name: irbesartan 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irbesartan 150 mg/day
Study: 31947529
Drug: Capsinoids (9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsinoids (9 mg daily for 3 months)
Study: 30920398
Drug: Both steroid
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both steroid injection and KT
Study: 28524341
Drug: Nitazoxanide 500
Normalized name: nitazoxanide 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitazoxanide 500 mg b.i.d., clarithromycin 500 mg b.i.d., and omeprazole 40 mg b.i.d. for 14 days
Study: 28524341
Drug: Metronidazole 500
Normalized name: metronidazole 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole 500 mg b.i.d., clarithromycin 500 mg b.i.d., and omeprazole 40 mg b.i.d. for 14 days
Study: 1098495
Drug: Oral dapsone
Normalized name: Dapsone
DrugBank: Dapsone (DB00250)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral dapsone (100 mg daily)
Study: 1098495
Drug: Intramuscular acedapsone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular acedapsone (225 mg every 12 weeks)
Study: 1098495
Drug: Oral dapsone
Normalized name: Dapsone
DrugBank: Dapsone (DB00250)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral dapsone (50 mg daily)
Study: 31416698
Drug: Intramuscular (IM)
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular (IM) injection of medetomidine (40 μg kg‐1)
Study: 28884566
Drug: Propofol medium-long
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol medium-long chain lipid emulsion injection (100 mg initial dose, then 0.54 mg/kg/h for 24 hours)
Study: 28884566
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no sedative measures)
Study: 23154587
Drug: Olmesartan add-on
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olmesartan add-on therapy
Study: 9166304
Drug: 1.5-g single
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5-g single oral dose of metronidazole
Study: 3908603
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no povidone iodine treatment)
Study: 3908603
Drug: Combined trials
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined trials including povidone iodine treatment
Study: 27277946
Drug: Daily multi-nutrient
Normalized name: Parasedge Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily multi-nutrient supplement (omega-3 fatty acids, calcium, selenium, B-11 vitamin, D-3 vitamin)
Study: 25512294
Drug: Midpalatal mini-implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midpalatal mini-implant anchorage system
Study: 25512294
Drug: Fixed appliance
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed appliance treatment with midpalatal mini-implant
Study: 22382876
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose of CEA
Study: 22382876
Drug: Anti-CEA IgA
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-CEA IgA antibodies
Study: 17765378
Drug: yi‐gan san
Approvals — FDA: no, EMA: no, PMDA: no
Description: yi‐gan san (YGS) at an average daily dosage of 6.4+/‐1.9 g (2.5‐7.5 g)
Study: 7921530
Drug: Beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate inhalation aerosol via collapsible spacer
Study: 7921530
Drug: Beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate inhalation aerosol via traditional large volume spacer
Study: 2457710
Drug: Continuous subcutaneous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous subcutaneous infusion (CSCI) of hydromorphone (HM)
Study: 28735699
Drug: Medication (sertraline)
Normalized name: Medicated Shampoo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication (sertraline)
Study: 24477837
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Cognitive Behavioral Therapy and Medication
Study: 25935877
Drug: Losartan (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan (50 mg when <50 kg, 100 mg otherwise)
Study: 24283598
Drug: Lisinopril (ACE-inhibitor)
Normalized name: Lisinopril
DrugBank: Lisinopril (DB00722)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lisinopril (ACE-inhibitor)
Study: 21737829
Drug: Injection of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of 1 ml of 5% hypertonic saline into biceps causing muscle pain
Study: 19194214
Drug: Calculated High
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calculated High Dose (CHD, 6.66‐7.4 MBq/g)
Study: 19194214
Drug: Calculated Low
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calculated Low Dose (CLD, 3.33‐3.70 MBq/g)
Study: 19194214
Drug: Fixed Low
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed Low Dose (FLD, 481 MBq)
Study: 9075106
Drug: Pulsed electromagnetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsed electromagnetic frequency (PEMF) therapy combined with Birmingham Containment Splint
Study: 9075106
Drug: Inactive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactive treatment coil (Control group)
Study: 25465932
Drug: n-3 PUFAs
Normalized name: 22:6(n-3)
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 PUFAs (4 g/day)
Study: 24140142
Drug: Intra-articular injection
Normalized name: PHOSPHORUS P-32 5 mCi in 1 mL INTRA-ARTICULAR INJECTION, SUSPENSION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular injection
Study: 16040211
Drug: CEE 0.625
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEE 0.625 mg plus MPA 2.5 mg daily orally for 12 months (hypertensive HRT group)
Study: 16040211
Drug: CEE 0.625
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEE 0.625 mg plus MPA 2.5 mg daily orally for 12 months (normotensive HRT group)
Study: 6354007
Drug: Terbutaline sulfate
Normalized name: Terbutaline Sulfate
DrugBank: Terbutaline (DB00871)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Terbutaline sulfate aerosol (two sprays, four times a day for 14 weeks)
Study: 6354007
Drug: Isoproterenol sulfate
Normalized name: Isoproterenol Sulfate
DrugBank: Isoprenaline (DB01064)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isoproterenol sulfate aerosol (two sprays, four times a day for 14 weeks)
Study: 30806102
Drug: CC plus
Normalized name: STATLOCK PICC PLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC plus metformin and L-carnitine
Study: 30806102
Drug: CC plus
Normalized name: STATLOCK PICC PLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC plus metformin and placebo
Study: 30806102
Drug: L-carnitine group
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine group
Study: 30379308
Drug: 7 mg
Normalized name: pectin 7 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7 mg of astaxanthin (ASTX)
Study: 30379308
Drug: 10 gr
Normalized name: Gelatin Capsules, 10 gr
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 gr of DC and 7 mg of ASTX ingested simultaneously
Study: 30379308
Drug: 10 gr
Normalized name: Gelatin Capsules, 10 gr
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 gr of a lycosomal formulation of DC containing 7 mg of co‐crystalized ASTX (L‐DC‐ASTX)
Study: 15809670
Drug: Intermittent androgen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent androgen deprivation therapy
Study: 22931259
Drug: Continuous androgen
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous androgen deprivation therapy
Study: 20673857
Drug: Myofascial Trigger
Normalized name: Anti-AML/SCCL-trigger monoclonal antibody
DrugBank: pM-81 (DB17432)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Myofascial Trigger Point (MTrP) therapy plus modified PNF stretching
Study: 15468166
Drug: Continuous androgen
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous androgen ablation after 14 months of protocol treatment
Study: 15468166
Drug: Intermittent androgen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent androgen ablation after 14 months of protocol treatment
Study: 15468166
Drug: 6 months
Normalized name: leuprolide 45 mg/6 months intramuscular kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 months of LHRH agonist with short-term antiandrogen treatment for flare-up prevention
Study: 8961038
Drug: Naturalistic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naturalistic treatment conditions
Study: 1743318
Drug: Both formulations
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both formulations (oral and vaginal)
Study: 6812003
Drug: Pristinamycin (2-3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pristinamycin (2-3 g/d)
Study: 6812003
Drug: Oxacillin (4-6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxacillin (4-6 g/d)
Study: 28052799
Drug: Albuterol MDPI
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol MDPI 90 μg per inhalation, two inhalations four times daily (total daily dose, 720 μg)
Study: 11554430
Drug: Dopegyt solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopegyt solution (250 mg/50 ml)
Study: 20944041
Drug: Topical permethrin
Normalized name: permethrin Topical Lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical permethrin (5% cream)
Study: 20944041
Drug: 7% sulfur
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7% sulfur preparation
Study: 8133853
Drug: Intravenous immune
Normalized name: Intravenous immune globulin (human)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immune globulin
Study: 6998552
Drug: Clonidine, 0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine, 0.05 mg twice daily
Study: 30954330
Drug: Neuropattern oriented
Normalized name: Oriental melon
DrugBank: Muskmelon (DB15611)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neuropattern oriented exploratory treatment (intervention group, IG)
Study: 30954330
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care (treatment as usual, standard group, SG)
Study: 26011509
Drug: CABG and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: CABG and optimal medical therapy (MED)
Study: 23803797
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (Control group) - 26 patients
Study: 19347726
Drug: XM02 (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: XM02 (5 microg/kg/day, subcutaneous, for at least 5 days and a maximum of 14 days)
Study: 19347726
Drug: Filgrastim (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Filgrastim (5 microg/kg/day, subcutaneous, for at least 5 days and a maximum of 14 days)